Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Bladder Cancer

  Free Subscription

Articles published in Clin Cancer Res

Retrieve available abstracts of 38 articles:
HTML format

Single Articles

    July 2021
  1. TEO MY, Rosenberg JE
    NECTIN4 heterogeneity and molecular diversity in bladder cancers: deconstructing the activity of an antibody-drug conjugate.
    Clin Cancer Res. 2021 Jul 19. pii: 1078-0432.CCR-21-1807.
    PubMed     Abstract available

    June 2021
  2. DAMRAUER JS, Roell KR, Smith MA, Sun X, et al
    Identification of a novel inflamed tumor microenvironment signature as a predictive biomarker of bacillus Calmette-Guerin immunotherapy in non-muscle invasive bladder cancer.
    Clin Cancer Res. 2021 Jun 11. pii: 1078-0432.CCR-21-0205.
    PubMed     Abstract available

    May 2021
    Myeloid Resistance is Not Futile: Biomarkers of Immunotherapy in Bladder Cancer.
    Clin Cancer Res. 2021 May 27. pii: 1078-0432.CCR-21-1011.
    PubMed     Abstract available

  4. HASANALI SL, Morera DS, Racine RR, Hennig M, et al
    HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer.
    Clin Cancer Res. 2021 May 24. pii: 1078-0432.CCR-21-0422.
    PubMed     Abstract available

  5. BORCSOK J, Diossy M, Sztupinszki Z, Prosz A, et al
    Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer.
    Clin Cancer Res. 2021 May 4. pii: 1078-0432.CCR-20-5037.
    PubMed     Abstract available

    February 2021
  6. FLAIG TW, Tangen CM, Daneshmand S, Alva AS, et al
    A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695).
    Clin Cancer Res. 2021 Feb 10. pii: 1078-0432.CCR-20-2409.
    PubMed     Abstract available

    February 2020
  7. LOKESHWAR VB, Morera DS, Hasanali SL, Yates TJ, et al
    A Novel Splice Variant of HYAL-4 Drives Malignant Transformation and Predicts Outcome in Bladder Cancer Patients.
    Clin Cancer Res. 2020 Feb 24. pii: 1078-0432.CCR-19-2912.
    PubMed     Abstract available

  8. KOBATAKE K, Ikeda K, Nakata Y, Yamasaki N, et al
    Kdm6a deficiency activates inflammatory pathways, promotes M2 macrophage polarization, and causes bladder cancer in cooperation with p53 dysfunction.
    Clin Cancer Res. 2020 Feb 11. pii: 1078-0432.CCR-19-2230.
    PubMed     Abstract available

    January 2020
  9. SHARMA P, Sohn J, Shin SJ, Oh DY, et al
    Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy.
    Clin Cancer Res. 2020;26:61-70.
    PubMed     Abstract available

    November 2019
  10. KATES M, Matoso A, Choi W, Baras AS, et al
    Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG Unresponsive Trials.
    Clin Cancer Res. 2019 Nov 11. pii: 1078-0432.CCR-19-1920.
    PubMed     Abstract available

    July 2019
  11. ANNELS NE, Mansfield D, Arif M, Ballesteros-Merino C, et al
    Viral targeting of non-muscle invasive bladder cancer and priming of anti-tumour immunity following intravesical Coxsackievirus A21.
    Clin Cancer Res. 2019 Jul 4. pii: 1078-0432.CCR-18-4022.
    PubMed     Abstract available

    April 2019
  12. BATISTA DA COSTA J, Gibb EA, Bivalacqua TJ, Liu Y, et al
    Molecular characterization of neuroendocrine-like bladder cancer.
    Clin Cancer Res. 2019 Apr 5. pii: 1078-0432.CCR-18-3558.
    PubMed     Abstract available

    March 2019
  13. KISS B, van den Berg NS, Ertsey R, McKenna K, et al
    CD47-targeted Near-Infrared Photoimmunotherapy for Human Bladder Cancer.
    Clin Cancer Res. 2019 Mar 19. pii: 1078-0432.CCR-18-3267.
    PubMed     Abstract available

  14. VANTAKU V, Dong J, Ambati CR, Perera D, et al
    sMulti-omics integration analysis robustly predicts high-grade patient survival and identifies CPT1B effect on fatty acid metabolism in Bladder Cancer.
    Clin Cancer Res. 2019 Mar 7. pii: 1078-0432.CCR-18-1515.
    PubMed     Abstract available

    February 2019
  15. GRIVAS P
    DNA Damage Response Gene Alterations in Urothelial Cancer: Ready for Practice?
    Clin Cancer Res. 2019;25:907-909.
    PubMed     Abstract available

    November 2018
  16. CHEN X, Xie R, Gu P, Huang M, et al
    Long noncoding RNA LBCS inhibits self-renewal and chemoresistance of bladder cancer stem cells through epigenetic silencing of SOX2.
    Clin Cancer Res. 2018 Nov 5. pii: 1078-0432.CCR-18-1656.
    PubMed     Abstract available

  17. WANG KJ, Wang C, Dai LH, Yang J, et al
    Targeting an Autocrine Regulatory Loop in Cancer Stem-Like Cells Impairs the Progression and Chemotherapy Resistance of Bladder Cancer.
    Clin Cancer Res. 2018 Nov 5. pii: 1078-0432.CCR-18-0586.
    PubMed     Abstract available

    October 2018
  18. KOSHKIN VS, Garcia JA, Reynolds JP, Elson P, et al
    Transcriptomic and protein analysis of small cell bladder cancer (SCBC) identifies prognostic biomarkers and DLL3 as a relevant therapeutic target.
    Clin Cancer Res. 2018 Oct 16. pii: 1078-0432.CCR-18-1278.
    PubMed     Abstract available

    September 2018
  19. RUBIO C, Martinez-Fernandez M, Segovia C, Lodewijk I, et al
    Cdk4/6-inhibitor as a novel therapeutic approach for advanced Bladder Cancer independently of RB1 status.
    Clin Cancer Res. 2018 Sep 21. pii: 1078-0432.CCR-18-0685.
    PubMed     Abstract available

  20. SEILER R, Gibb EA, Wang NQ, Oo HZ, et al
    Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.
    Clin Cancer Res. 2018 Sep 17. pii: 1078-0432.CCR-18-1106.
    PubMed     Abstract available

    August 2018
  21. RAJA R, Kuziora M, Brohawn P, Higgs BW, et al
    Early reduction in ctDNA predicts survival in lung and bladder cancer patients treated with durvalumab.
    Clin Cancer Res. 2018 Aug 9. pii: 1078-0432.CCR-18-0386.
    PubMed     Abstract available

    July 2018
  22. BIELLI P, Panzeri V, Lattanzio R, Mutascio S, et al
    The splicing factor PTBP1 promotes expression of oncogenic splice variants and predicts poor prognosis in patients with non-muscle invasive bladder cancer.
    Clin Cancer Res. 2018 Jul 16. pii: 1078-0432.CCR-17-3850.
    PubMed     Abstract available

  23. LI Q, Damish A, Frazier ZJ, Liu D, et al
    ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer.
    Clin Cancer Res. 2018 Jul 6. pii: 1078-0432.CCR-18-1001.
    PubMed     Abstract available

    June 2018
  24. LELO A, Prip F, Harris BT, Solomon D, et al
    STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer.
    Clin Cancer Res. 2018 Jun 28. pii: 1078-0432.CCR-17-3244.
    PubMed     Abstract available

    March 2018
  25. FU H, Zhu Y, Wang Y, Liu Z, et al
    Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle Invasive Bladder Cancer.
    Clin Cancer Res. 2018 Mar 7. pii: 1078-0432.CCR-17-2687.
    PubMed     Abstract available

    January 2018
  26. VAN KESSEL KE, van der Keur KA, Dyrskjot L, Algaba F, et al
    Molecular markers increase precision of the European Association of Urology non-muscle invasive bladder cancer progression risk groups.
    Clin Cancer Res. 2018 Jan 24. pii: 1078-0432.CCR-17-2719.
    PubMed     Abstract available

    December 2017
  27. CHEN CH, Changou C, Hsieh TH, Lee YC, et al
    Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer.
    Clin Cancer Res. 2017 Dec 8. pii: 1078-0432.CCR-17-2066.
    PubMed     Abstract available

    September 2017
  28. MARTINEZ VG, Rubio C, Martinez-Fernandez M, Segovia C, et al
    BMP4 induces M2 macrophage polarization and favors tumor progression in bladder cancer.
    Clin Cancer Res. 2017 Sep 19. pii: clincanres.1004.2017.
    PubMed     Abstract available

  29. WU S, Zheng J, Li Y, Yu H, et al
    A Radiomics Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer.
    Clin Cancer Res. 2017 Sep 5. pii: clincanres.1510.2017.
    PubMed     Abstract available

    August 2017
  30. KATES M, Date A, Yoshida T, Afzal U, et al
    Preclincial Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer.
    Clin Cancer Res. 2017 Aug 14. pii: clincanres.1082.2017.
    PubMed     Abstract available

  31. ZENG S, Zhu Y, Ma AH, Yu W, et al
    The Phosphatidylinositol 3-kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.
    Clin Cancer Res. 2017 Aug 14. pii: clincanres.0033.2017.
    PubMed     Abstract available

  32. WEN T, Yang Z, He L, Lin K, et al
    The KMT1A-GATA3-STAT3 circuit is a novel self-renewal signaling of human bladder cancer stem cells.
    Clin Cancer Res. 2017 Aug 1. pii: clincanres.0882.2017.
    PubMed     Abstract available

    July 2017
  33. VANDEKERKHOVE GR, Todenhofer T, Annala M, Struss WJ, et al
    <span style="font-weight: 400;">Circulating tumor DNA reveals clinically-actionable somatic genome of metastatic bladder cancer</span>.
    Clin Cancer Res. 2017 Jul 31. pii: clincanres.1140.2017.
    PubMed     Abstract available

    April 2017
  34. YANG L, Taylor J, Eustace A, Irlam J, et al
    A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High Risk Bladder Cancer Patients.
    Clin Cancer Res. 2017 Apr 11. pii: clincanres.0038.2017.
    PubMed     Abstract available

    February 2017
  35. SIN ML, Mach KE, Sinha R, Wu F, et al
    Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics.
    Clin Cancer Res. 2017 Feb 13. pii: clincanres.2610.2016.
    PubMed     Abstract available

    January 2017
  36. WANG WJ, Li CF, Chu YY, Wang YH, et al
    Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder.
    Clin Cancer Res. 2017;23:503-513.
    PubMed     Abstract available

    November 2016
  37. INMAN BA, Longo TA, Ramalingam S, Harrison MR, et al
    Atezolizumab: a PD-L1 blocking antibody for bladder cancer.
    Clin Cancer Res. 2016 Nov 30. pii: clincanres.1417.2016.
    PubMed     Abstract available

    March 2016
  38. GUIN S, Ru Y, Agarwal N, Lew CR, et al
    Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis.
    Clin Cancer Res. 2016;22:1274-83.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.